{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:26:00Z","timestamp":1790767560126,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100013126","name":"Psoriasis Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013126","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13555-025-01578-w","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:36:30Z","timestamp":1761917790000},"page":"191-204","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Serious Infection Risk with Systemic Treatments for Psoriasis: A Systematic Review and Network Meta-analysis Combining Randomised and Non-randomised Evidence"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3149-5750","authenticated-orcid":false,"given":"Heber Rew Bright","family":"Bright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8916-9093","authenticated-orcid":false,"given":"Duc Binh","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Zahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7352-6454","authenticated-orcid":false,"given":"Leila","family":"Motedayen Aval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Manupati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9918-1144","authenticated-orcid":false,"given":"Catherine H.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0073-1885","authenticated-orcid":false,"given":"Lesley S.","family":"Exton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2510-9964","authenticated-orcid":false,"given":"Martinsixtus","family":"Ezejimofor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-074X","authenticated-orcid":false,"given":"Zenas Z. N.","family":"Yiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"1578_CR1","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.anai.2023.02.010","volume":"130","author":"L Cannon","year":"2023","unstructured":"Cannon L, Pan A, Kovalick L, Sarkissian A, Wu EY. Secondary immunodeficiencies and infectious considerations of biologic immunomodulatory therapies. Ann Allergy Asthma Immunol. 2023;130:718\u201326.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1578_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14498","volume":"34","author":"A Sadeghinia","year":"2021","unstructured":"Sadeghinia A, Daneshpazhooh M. Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review. Dermatol Ther. 2021;34:e14498.","journal-title":"Dermatol Ther"},{"key":"1578_CR3","unstructured":"US Food and Drug Adminstration. Efalizumab (marketed as Raptiva) Information. FDA. 2024. https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/efalizumab-marketed-raptiva-information. Accessed July 4, 2024."},{"key":"1578_CR4","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/j.jid.2016.03.035","volume":"136","author":"ZZN Yiu","year":"2016","unstructured":"Yiu ZZN, Exton LS, Jabbar-Lopez Z, et al. Risk of serious infections in patients with psoriasis on biologic therapies: a systematic review and meta-analysis. J Invest Dermatol. 2016;136:1584\u201391.","journal-title":"J Invest Dermatol"},{"key":"1578_CR5","doi-asserted-by":"publisher","first-page":"204062232312062","DOI":"10.1177\/20406223231206225","volume":"14","author":"H-Y Chiu","year":"2023","unstructured":"Chiu H-Y, Hung Y-T, Huang Y-H. Comparative short-term risks of infection and serious infection in patients receiving biologic and small-molecule therapies for psoriasis and psoriatic arthritis: a systemic review and network meta-analysis of randomized controlled trials. Ther Adv Chronic Dis. 2023;14:20406223231206224.","journal-title":"Ther Adv Chronic Dis"},{"key":"1578_CR6","doi-asserted-by":"publisher","first-page":"vii54","DOI":"10.1093\/rheumatology\/key109","volume":"57","author":"S Monti","year":"2018","unstructured":"Monti S, Grosso V, Todoerti M, Caporali R. Randomized controlled trials and real-world data: differences and similarities to untangle literature data. Rheumatology. 2018;57:vii54\u20138.","journal-title":"Rheumatology"},{"key":"1578_CR7","doi-asserted-by":"publisher","unstructured":"Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020;1(1):CD011535. https:\/\/doi.org\/10.1002\/14651858.CD011535.pub5\/full. Accessed Aug 5, 2024.","DOI":"10.1002\/14651858.CD011535.pub5\/full"},{"key":"1578_CR8","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","volume":"29","author":"S Dias","year":"2010","unstructured":"Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29:932\u201344.","journal-title":"Stat Med"},{"key":"1578_CR9","unstructured":"16.9.2 Studies with zero-cell counts. https:\/\/handbook-5-1.cochrane.org\/v5.0.2\/chapter_16\/16_9_2_studies_with_zero_cell_counts.htm. Accessed Sept 3, 2024."},{"key":"1578_CR10","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/sim.1761","volume":"23","author":"MJ Sweeting","year":"2004","unstructured":"Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23:1351\u201375.","journal-title":"Stat Med"},{"key":"1578_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G R\u00fccker","year":"2015","unstructured":"R\u00fccker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:58.","journal-title":"BMC Med Res Methodol"},{"key":"1578_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou A, Higgins JPT, Papakonstantinou T, et al. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020;17:e1003082.","journal-title":"PLoS Med"},{"key":"1578_CR13","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamadermatol.2021.2599","volume":"157","author":"L Penso","year":"2021","unstructured":"Penso L, Dray-Spira R, Weill A, Pina Vegas L, Zureik M, Sbidian E. Association between biologics use and risk of serious infection in patients with psoriasis. JAMA Dermatol. 2021;157:1056\u201365.","journal-title":"JAMA Dermatol"},{"key":"1578_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/bjd.17036","volume":"180","author":"ZZN Yiu","year":"2019","unstructured":"Yiu ZZN, Ashcroft DM, Evans I, et al. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Br J Dermatol. 2019;180:329\u201337.","journal-title":"Br J Dermatol"},{"key":"1578_CR15","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1002\/acr.24630","volume":"74","author":"Y Jin","year":"2022","unstructured":"Jin Y, Lee H, Lee MP, et al. Risk of hospitalization for serious infection after initiation of ustekinumab or other biologics in patients with psoriasis or psoriatic arthritis. Arthritis Care Res (Hoboken). 2022;74:1792\u2013805.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1578_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1001\/jamadermatol.2022.6325","volume":"159","author":"MC Schneeweiss","year":"2023","unstructured":"Schneeweiss MC, Savage TJ, Wyss R, et al. Risk of infection in children with psoriasis receiving treatment with ustekinumab, etanercept, or methotrexate before and after labeling expansion. JAMA Dermatol. 2023;159:289\u201398.","journal-title":"JAMA Dermatol"},{"key":"1578_CR17","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1001\/jamadermatol.2019.1121","volume":"155","author":"ED Dommasch","year":"2019","unstructured":"Dommasch ED, Kim SC, Lee MP, Gagne JJ. Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis. JAMA Dermatol. 2019;155:1142\u201352.","journal-title":"JAMA Dermatol"},{"key":"1578_CR18","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jid.2017.10.005","volume":"138","author":"ZZN Yiu","year":"2018","unstructured":"Yiu ZZN, Smith CH, Ashcroft DM, et al. Risk of serious infection in patients with psoriasis receiving biologic therapies: a prospective cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2018;138:534\u201341.","journal-title":"J Invest Dermatol"},{"key":"1578_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109248","volume":"112","author":"C Yu","year":"2022","unstructured":"Yu C, Zhang F, Ding Y, et al. A randomized, double-blind phase\u00a0III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis. Int Immunopharmacol. 2022;112:109248.","journal-title":"Int Immunopharmacol"},{"key":"1578_CR20","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","volume":"385","author":"K Reich","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385:142\u201352.","journal-title":"N Engl J Med"},{"key":"1578_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase\u00a03 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88:29\u201339.","journal-title":"J Am Acad Dermatol"},{"key":"1578_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.19341","volume":"184","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase\u00a0III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184:50\u20139.","journal-title":"Br J Dermatol"},{"key":"1578_CR23","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase\u00a03, randomised controlled trial. Lancet. 2019;394:831\u20139.","journal-title":"Lancet"},{"key":"1578_CR24","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","volume":"376","author":"KA Papp","year":"2017","unstructured":"Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376:1551\u201360.","journal-title":"N Engl J Med"},{"key":"1578_CR25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/annrheumdis-2019-216102","volume":"79","author":"X Li","year":"2020","unstructured":"Li X, Andersen KM, Chang H-Y, Curtis JR, Alexander GC. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. Ann Rheum Dis. 2020;79:285\u201391.","journal-title":"Ann Rheum Dis"},{"key":"1578_CR26","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1111\/jdv.19328","volume":"37","author":"K Kridin","year":"2023","unstructured":"Kridin K, Zirpel H, Mruwat N, Ludwig RJ, Thaci D. Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors\u2014a population-based study. J Eur Acad Dermatol Venereol. 2023;37:2319\u201326.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1578_CR27","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","volume":"3","author":"MA Gardam","year":"2003","unstructured":"Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:148\u201355.","journal-title":"Lancet Infect Dis"},{"key":"1578_CR28","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"1578_CR29","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jid.2016.08.034","volume":"137","author":"P D\u00e1vila-Seijo","year":"2017","unstructured":"D\u00e1vila-Seijo P, Dauden E, Descalzo MA, et al. Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: findings from the BIOBADADERM registry. J Invest Dermatol. 2017;137:313\u201321.","journal-title":"J Invest Dermatol"},{"key":"1578_CR30","doi-asserted-by":"crossref","unstructured":"Djulbegovic B, Koletsi D, Hozo I, et al. High certainty evidence is stable and trustworthy, whereas evidence of moderate or lower certainty may be equally prone to being unstable. J Clin Epidemiol. 2024;171. https:\/\/www.jclinepi.com\/article\/S0895-4356(24)00147-1\/fulltext. Accessed Sept 3, 2024.","DOI":"10.1016\/j.jclinepi.2024.111392"},{"key":"1578_CR31","unstructured":"Chapter 10: Analysing data and undertaking meta-analyses. https:\/\/training.cochrane.org\/handbook\/current\/chapter-10. Accessed Sept 3, 2024."},{"key":"1578_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1136\/bmjebm-2020-111493","volume":"27","author":"G Sarri","year":"2022","unstructured":"Sarri G, Patorno E, Yuan H, et al. Framework for the synthesis of non-randomised studies and randomised controlled trials: a guidance on conducting a systematic review and meta-analysis for healthcare decision making. BMJ Evid Based Med. 2022;27:109\u201319.","journal-title":"BMJ Evid Based Med"},{"key":"1578_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12874-023-01925-5","volume":"23","author":"H Hussein","year":"2023","unstructured":"Hussein H, Abrams KR, Gray LJ, Anwer S, Dias S, Bujkiewicz S. Hierarchical network meta-analysis models for synthesis of evidence from randomised and non-randomised studies. BMC Med Res Methodol. 2023;23:97.","journal-title":"BMC Med Res Methodol"},{"key":"1578_CR34","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1002\/sim.7223","volume":"36","author":"O Efthimiou","year":"2017","unstructured":"Efthimiou O, Mavridis D, Debray TPA, et al. Combining randomized and non-randomized evidence in network meta-analysis. Stat Med. 2017;36:1210\u201326.","journal-title":"Stat Med"},{"key":"1578_CR35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jclinepi.2022.06.011","volume":"150","author":"S Bujkiewicz","year":"2022","unstructured":"Bujkiewicz S, Singh J, Wheaton L, et al. Bridging disconnected networks of first and second lines of biologic therapies in rheumatoid arthritis with registry data: bayesian evidence synthesis with target trial emulation. J Clin Epidemiol. 2022;150:171\u20138.","journal-title":"J Clin Epidemiol"},{"key":"1578_CR36","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"JB Galloway","year":"2011","unstructured":"Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6\u00a0months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50:124\u201331.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01578-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01578-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01578-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:40:16Z","timestamp":1770190816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01578-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1578"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01578-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Richard B Warren is in receipt of either research grants and\/or act as a consultant for\u00a0AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DiCE, Galderma, GSK, Janssen, Lilly, Leo, Meiji Pharma, Novartis, Pfizer, RAPT pharmaceuticals, Sanofi, Sun Pharma, UCB & UNION.\u00a0Richard B Warren is an Editor-in-Chief of\n                      Dermatology and Therapy\n                      . Richard Warren was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Catherine H Smith is in receipt of an NIHR Senior Investigator award and research funding as part of EC funded consortia with multiple industry partners (Biomap-imi.eu; Hippocrates-imi.eu). Lesley S Exton and Martinsixtus Ezejimofor are involved in the development of clinical guidelines for biologic therapy for psoriasis. Zenas ZN Yiu, Mark Lunt, Heber Rew Bright Bright, Duc Binh Phan, Amna Zahid, Shilpa Manupati and Leila Motedayen Aval declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}